Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin for Minimizing Post-excisional Scarring
NCT02623829Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Dec 2015
- Primary completion
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in scarring (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Modified Manchester Scar Scale at 6 months. Started Dec 2015; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
scarring
Beyond the preview
Go deeper on NCT02623829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623829.